Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 0

iCombined Therapy in Diabetic Macular Edema

Diyabetik MakülaÖdeminde KombineTedav

Pages
62–66
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we discussed application of combined DME therapy in order to potentialise the current methods and degrade side effects

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic macular edema (DME) is the most important ocular complication of diabetes mellitus that can result with visual loss.
📊
Key Findings & Data:Many factors are responsible in ethiopathogenesis and ideal treatment is not mentioned yet.
💡
Conclusion & Impact:In this review, we discussed application of combined DME therapy in order to potentialise the current methods and degrade side effects
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diabetic macular edema (DME) is the most important ocular complication of diabetes mellitus that can result with visual loss. Many factors are responsible in ethiopathogenesis and ideal treatment is not mentioned yet. Nowadays, laser photocoagulation, intravitreal or periocular injection, pars plana vitrectomy are among therapeutic options. In this review, we discussed application of combined DME therapy in order to potentialise the current methods and degrade side effects

Özet

Diyabetik maküla ödemi (DMÖ) diyabetes mellitusun görme kaybıyla sonlanabilen en önemli oküler komplikasyonlarındandır. Etyopatogenezinde çok sayıda etkenin rol oynadığı DMÖ'nin ideal tedavisi de henüz bulunabilmiş değildir. Günümüzde lazer fotokoagülasyon, intravitreal veya perioküler enjeksiyon, pars plana vitrektomi tedavi seçenekleri arasındadır. Bu makalede mevcut yöntemlerin etkisini artırmak ve yan etkilerini en aza indirgemek amacıyla uygulanan kombine DMÖ tedavileri tartışılmıştır

🔖

Cite This Article

DEMİRCAN, N. (2015). iCombined Therapy in Diabetic Macular Edema. Retina-Vitreus, Cilt: 23 - Sayı: 0, 62–66. https://ajindex.com/articles/308035

References (12)

  1. Jain A, Varshney N, Smith C. The evolving treatment options for diabetic macular edema. Int J of Inflam 2013;1:1-10. Hammes HP. Optimal treatment of diabetic retinopathy. Ther Adv En- docrinol Metab 2013;4:61-71.
  2. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: Pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32. Lang GE. Diabetic macular edema. Ophthalmologica 2012;227:21-9.
  3. Ho AC, Scott IU, Kim SJ, et al. Anti-Vascular endothelial growth factor pharmacotheraphy for diabetic macular edema (A report by the American Academy of Ophthalmology). Ophthalmology 2012;119:2179-88.
  4. Thomas BJ, Shienbaum G, Boyer DS, et al. Evolving strategies in the management of diabetic macular edema: clinical trials and current ma- nagement. Can J Ophthalmol 2013;48:22-30.
  5. Bandello F, Cunha-Vaz J, Chong NV, et al. New approaches for the treat- ment of diabetic macular oedema: recommendations by an expert panel. Eye 2012;26:485-93.
  6. Tigrel G, Sarıcı AM: Diyabetik maküla ödeminin tedavisinde kombine tedaviler. T Klin J Ophthalmol 2013;6:113-6.
  7. Lee SJ, Kim ET, Moon YS. Intravitreal bevacizumab versus combined with macular photocoagulation in diabetic macular edema. Korean J Ophthalmol 2011;25:299-304.
  8. Arevalo JF, Lasave AF, Wu L, et al. Intravitreal bevacizumab plus grid la- ser photocoagulation or intravitreal bevacizumab or grid laser photocoa- gulation for diffuse diabetic macular edema (Results of the Pan-American collaborative retina study group at 24 months). Retina 2013;33:403-13.
  9. Solaiman K, Diab MM, Dabour SA. Repeated intravitrel bevacizumab in- jection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema. Retina 2013;33:1623-9.
  10. Mitchell P, Bandello F, Schmidt-Erfurt U, et al. The Restore Study. Ra- nibizumab monotheraphy or combined with laser versus laser monothe- raphy for diabetic macular edema. Ophthalmology 2011;118:615-25.
  11. Lang GE, Berta A, Eldem B, et al. Two-year safety and efficacy of ra- nibizumab 0.5 mg in diabetic macular edema (Interim analysis of the RESTORE extension study). Ophthalmology 2013;120:2004-12. önemli faktörlerdir.37 Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic ma- cular edema. Clinical Ophthalmol 2011;5:1011-16.
  12. Shoeibi N, Ahmadieh H, Entezari M, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: Long term results of a clinical trial. J Ophthalm